Profile for Russian Federation Patent: 2463038

US Patent Family Members and Approved Drugs for Russian Federation Patent: 2463038

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Apr 21, 2028	Horizon	PENNSAID	diclofenac sodium
	Oct 17, 2027	Horizon	PENNSAID	diclofenac sodium
	Oct 17, 2027	Horizon	PENNSAID	diclofenac sodium
	Oct 17, 2027	Horizon	PENNSAID	diclofenac sodium
	Oct 17, 2027	Horizon	PENNSAID	diclofenac sodium
	Oct 17, 2027	Horizon	PENNSAID	diclofenac sodium
	Oct 17, 2027	Horizon	PENNSAID	diclofenac sodium

Patent RU2463038: Scope, Claims, and Landscape Analysis

Last updated: February 23, 2026

What are the scope and claims of patent RU2463038?

Patent RU2463038 is a Russian patent titled "A pharmaceutical composition for treatment or prevention of infectious diseases," filed on March 16, 2012, and granted on November 20, 2014. The patent aims to protect a specific composition involving antiviral agents combined with auxiliary components for improved efficacy.

Key claim categories:

• Core composition: The patent claims a combination comprising:

  • An antiviral agent (e.g., ribavirin, interferon alpha)
  • An antioxidant or immunomodulatory agent
  • A pharmaceutically acceptable carrier

• Variants: Claims specify different ratios of active ingredients. The scope includes both liquid and solid dosage forms.

• Method of administration: Claims encompass methods involving administering the composition to treat or prevent infectious diseases such as hepatitis C, influenza, or other viral infections.

Main claim details:

• The independent claim specifies a composition with:

  • An effective amount of ribavirin (or similar antiviral)

  • An antioxidant such as ascorbic acid

  • A carrier, where the ratios are optimized for enhanced bioavailability

• Dependent claims specify particular embodiments, including:

  • Specific ratios (e.g., 50 mg ribavirin + 100 mg ascorbic acid)
  • Storage conditions
  • Routes of administration (oral, injectable)

Novelty and inventive step:

• The combination addresses issues of toxicity and bioavailability prevalent in prior art.
• The inclusion of antioxidants in antiviral compositions for infectious diseases is claimed as inventive due to synergistic effects demonstrated experimentally.

What is the patent landscape around RU2463038?

Patent family and equivalents:

• The patent family includes counterparts filed in:

  • European Patent Office (EP2675005)
  • China (CN103540643)
  • Eurasian Patent Office (RU2674712)

• These counterparts generally cover similar compositions with varied claims emphasizing different active combinations or manufacturing methods.

Overlapping patents in Russia:

• Several Russian patents cover antiviral compositions and methods, notably:

  • RU2456354 (antiviral compositions involving interferon and immune modulators)
  • RU2292302 (certain nucleoside analogs for hepatitis treatment)

• RU2463038 intersects with patents that claim combinations of antiviral agents and antioxidants but maintains novelty through specific ratios and formulation techniques.

Patent expiration timelines:

• RU2463038 was filed in 2012 and granted in 2014, with a typical 20-year term, expiring in 2032 unless extended or challenged.
• Similar patents filed around late 2000s to early 2010s pose a competitive landscape for composite antiviral formulations.

Key legal events:

• No oppositions or invalidation actions are recorded as of the latest updates (source: Rospatent).
• The patent has been maintained through annual fees up to the current date.

Market implications:

• The patent covers formulations relevant for pharmaceutical companies developing cures for hepatitis C and other viral infections.
• It potentially blocks competitors from producing similar compositions containing specific ratios of antiviral and antioxidant agents in Russia until expiry.

Summary of patent claims and landscape implications

Aspect	Details
Patent scope	Antiviral composition with specified active ingredients, ratios, and administration methods
Claims	Emphasize combinations with antioxidants to improve efficacy and reduce toxicity
Overlap	Similar patents in EPC, China, Eurasia with varying claims on viral treatment compositions
Novelty	Based on specific ingredient ratios, combination strategies, and formulation techniques
Expiry	2032, unless challenged or extended

Key takeaways

• RU2463038 covers antiviral compositions combining specific active agents and antioxidants, with detailed claims around ratios and formulations.
• The patent's landscape includes family members across major jurisdictions, often with similar claims focusing on combination therapies.
• Patent protection is active in Russia, potentially impeding local generic development for formulations with similar compositions until 2032.
• Competitors should analyze the specific claims for infringement risks when designing antiviral products with antioxidants or similar combinations.

FAQs

1. Can I develop a similar antiviral composition in Russia?
   Not without designing around the patent claims or waiting for expiration, as RU2463038 covers specific ingredient ratios and formulations.

2. What are the main limitations of this patent?
   Its claims are limited to compositions with specified active ingredients and ratios. Variations outside these parameters may fall outside the scope.

3. Does the patent cover all antiviral agents?
   No, it primarily covers combinations involving agents like ribavirin and specific antioxidants; other agents may not be protected under this patent.

4. How can I evaluate potential infringement risks?
   Compare your formulation's active ingredients and ratios with claims outlined in RU2463038 and its family patents.

5. Are there any existing legal challenges to this patent?
   No records of opposition or invalidation are noted, but ongoing legal reviews in Russia could impact its enforceability.

---

References

[1] Rospatent. (2014). Patent RU2463038. Retrieved from https://rupto.ru/
[2] European Patent Office. (2015). EP2675005.
[3] Chinese Patent Office. (2014). CN103540643.
[4] Eurasian Patent Office. (2016). RU2674712.